CR20220116A - Compuestos heterocíclicos - Google Patents

Compuestos heterocíclicos

Info

Publication number
CR20220116A
CR20220116A CR20220116A CR20220116A CR20220116A CR 20220116 A CR20220116 A CR 20220116A CR 20220116 A CR20220116 A CR 20220116A CR 20220116 A CR20220116 A CR 20220116A CR 20220116 A CR20220116 A CR 20220116A
Authority
CR
Costa Rica
Prior art keywords
compounds
sup
heterocyclic compounds
methods
general formula
Prior art date
Application number
CR20220116A
Other languages
English (en)
Inventor
Benoit Hornsperger
Guofu Liu
Fionn O`Hara
Bernd Kuhn
Uwe Grether
Luca Gobbi
Martin Kuratli
Steven Paul Hanlon
Martin Ritter
Carsten Kroll
Hans Richter
Joerg Benz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72659185&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20220116(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220116A publication Critical patent/CR20220116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (I): en donde A, L, Q, U, V, W, X, Z, m, n y R<sup>1</sup> a R<sup>4</sup> son tal como se indica en la presente, en donde las composiciones incluyen los compuestos, procedimientos de fabricación de los compuestos y métodos de uso de los compuestos.
CR20220116A 2019-09-23 2020-09-21 Compuestos heterocíclicos CR20220116A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19198974 2019-09-23
CN2020109184 2020-08-14
PCT/EP2020/076228 WO2021058416A1 (en) 2019-09-23 2020-09-21 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
CR20220116A true CR20220116A (es) 2022-04-20

Family

ID=72659185

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220116A CR20220116A (es) 2019-09-23 2020-09-21 Compuestos heterocíclicos

Country Status (16)

Country Link
US (2) US20210107921A1 (es)
EP (1) EP4034239A1 (es)
JP (1) JP2022549810A (es)
KR (1) KR20220066894A (es)
CN (1) CN114401969A (es)
AU (1) AU2020355507A1 (es)
BR (1) BR112022003982A2 (es)
CA (1) CA3155161A1 (es)
CO (1) CO2022003062A2 (es)
CR (1) CR20220116A (es)
IL (1) IL289617A (es)
MX (1) MX2022003023A (es)
PE (1) PE20221450A1 (es)
PH (1) PH12022550433A1 (es)
TW (1) TW202120502A (es)
WO (1) WO2021058416A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
CN114072405A (zh) 2019-07-03 2022-02-18 豪夫迈·罗氏有限公司 杂环单酰基甘油脂肪酶(magl)抑制剂
KR20220034104A (ko) 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
PE20231372A1 (es) 2020-09-03 2023-09-07 Hoffmann La Roche Compuestos heterociclicos
WO2025153656A1 (en) * 2024-01-19 2025-07-24 F. Hoffmann-La Roche Ag Heterocyclic inhibitors of monoacylglycerol lipase (magl)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
WO2007117557A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
US10106556B2 (en) * 2015-03-30 2018-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20180148429A1 (en) 2015-05-13 2018-05-31 Selvita S.A. Substituted quinoxaline derivatives
EP3717477B1 (en) * 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
TW201930300A (zh) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
EP3737680A1 (en) * 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
DK3768684T3 (da) * 2018-03-22 2023-04-24 Hoffmann La Roche Oxazin-monoacylglycerol-lipase (MAGL)-hæmmere
MY210507A (en) * 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
EP3837264A1 (en) * 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors

Also Published As

Publication number Publication date
CA3155161A1 (en) 2021-04-01
US20220267349A1 (en) 2022-08-25
WO2021058416A1 (en) 2021-04-01
CO2022003062A2 (es) 2022-04-19
CN114401969A (zh) 2022-04-26
US20210107921A1 (en) 2021-04-15
AU2020355507A1 (en) 2022-02-17
IL289617A (en) 2022-03-01
PH12022550433A1 (en) 2024-01-29
MX2022003023A (es) 2022-04-07
PE20221450A1 (es) 2022-09-21
JP2022549810A (ja) 2022-11-29
KR20220066894A (ko) 2022-05-24
EP4034239A1 (en) 2022-08-03
TW202120502A (zh) 2021-06-01
BR112022003982A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
CO2022003062A2 (es) Compuestos heterocíclicos
CL2022000556A1 (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
CR20230115A (es) Compuestos heterocíclicos
CL2020002423A1 (es) Nuevos compuestos heterocíclicos
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
CO2021002382A2 (es) Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
CO2022002000A2 (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
CO2022002336A2 (es) Compuestos heterocíclicos
DOP2010000046A (es) Compuestos de biciclolactama sustituida
CL2008002132A1 (es) Compuestos derivados de sulfonamidas, moduladores de trpm8; composiciones farmaceuticas que comprenden a dichos compuestos; y uso de dichos compuestos en el tratamiento del dolor neuropatico, dolor inflamatorio, ansiedad, depresion, hiperalgesia inflamatoria, entre otras.
CO2022002339A2 (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
CL2023002429A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
CL2022002661A1 (es) Derivados de benzodiazepinas como pam de gaba a gamma1
PY2074467A (es) Compuestos herbicidas
BR112021026899A2 (pt) Compostos heterocíclicos
PY1987737A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
PY2265946A (es) Nueva (3-quinolil)-quinazolina
PY1986693A (es) Compuestos herbicidas
CL2021000486A1 (es) Derivados de heteroarilo bicíclicos
PY2041444A (es) Compuestos herbicidas
AR130168A1 (es) Derivados bicíclicos de tetrahidrotiazepina
CO2025001103A2 (es) Derivados de tetrahidrotiazepina bicíclicos
UY38758A (es) Hidroxiisoxazolinas y derivados de las mismas